Compounds

One hub per molecule: regulatory status as of today, pharmacokinetic parameters with sources, headline trial results and every tool and guide for that compound.

Updated by the GLP Ladder Editorial Team. Editorial policy.

Compounds covered

  • Retatrutide Investigational

    GIP, GLP-1 and glucagon receptor agonist (a "triple agonist"). Investigational. Not FDA approved; available legally only in Lilly clinical trials.

    6 dayshalf-life

  • Tirzepatide FDA approved

    GIP and GLP-1 receptor agonist (a "dual agonist"). FDA approved as Mounjaro (type 2 diabetes) and Zepbound (weight management, obstructive sleep apnea).

    5 dayshalf-life

  • Semaglutide FDA approved

    GLP-1 receptor agonist. FDA approved as Ozempic (type 2 diabetes) and Wegovy (weight management, cardiovascular risk reduction).

    7 dayshalf-life